



Many new treatments for diseases such as cancer, kidney and heart disease, and hepatitis have arisen from research on HIV/AIDS.

amfAR™
MAKING AIDS HISTORY



Since the beginning of the epidemic, AIDS research has been a testing ground for new concepts and technologies in drug development, diagnostics, and disease prevention. Drugs developed to combat HIV and to treat AIDS have helped improve and prolong the lives of countless people worldwide.

But discoveries made in one area of research often benefit the study and treatment of a wide variety of human diseases. The fact is that many new treatments for diseases such as **cancer**, **hepatitis**, **heart and kidney disease**, and **osteoporosis** have arisen from research aimed at preventing, diagnosing, and treating HIV/AIDS. This research has also provided insights into new ways of treating **autoimmune diseases** and **severe vision loss**.

Are there serious diseases unrelated to HIV that have been put into remission or even cured as a direct result of AIDS research?



Absolutely, and some recent examples have been very dramatic. In 2012, a young girl with acute leukemia wasn't responding to conventional treatments and was on the brink of death. But then she was given an experimental treatment using an anti-cancer gene that could


only be delivered to her cells using disabled HIV as a carrier. Within weeks she was in remission and she remains cancer-free.

In 2014, a Utah man with the same type of aggressive leukemia received a similar treatment using disabled HIV and he, too, is now cancer-free.

Additionally, six HIV-negative children with usually fatal **genetic immune disorders** (Wiskott-Aldrich syndrome, severe combined immuno-deficiency, and chronic granulomatous disease) were cured using similar targeted gene ther-

apies, all of which employed inactivated HIV.

"An anti-cancer gene could only be delivered to her cells using disabled HIV as a carrier."



Have drugs specifically developed to treat HIV been used in the treatment of other infections or diseases?



Yes. HIV/AIDS therapies are critical in the treatment of other diseases. For example, three drugs developed to treat HIV—lamivudine, tenofovir, and entecavir—are now the mainstays of therapy for **hepatitis B virus** (HBV) infections. Another antiviral drug called adefovir, which failed as an HIV treatment, was found to suppress HBV at much lower dosages and has been approved for the treatment of chronic HBV disease. More recently, a drug called sofosbuvir that is modeled on HIV reverse transcriptase inhibitors, one of the main classes of anti-HIV drugs, is being used to treat and cure **hepatitis C**.

How else is AIDS research helping with other diseases?

"The small arteries of a two-year-old child with AIDS often resemble those of a 50-year-old man."


HIV-positive children and adults, both on and off certain anti-HIV medications, can suffer **heart attacks** and **strokes** because HIV appears to affect small blood vessels in the heart and the brain, which makes these patients vulnerable to spasm, blood clots, and early atherosclerosis (buildup of fats, cholesterol, and other substances in the arteries). The small arteries of a two-year-old child with AIDS often resemble those of a 50-year-old man.

And in HIV infection, a process of programmed cell death injures the cells that line the small blood vessels of the heart. Inflammation appears to play a significant role in this process, as it does in non-HIV-infected individuals. Methods of controlling

inflammation and detecting it early should limit these damaging processes in all affected individuals.

Research aimed at developing a vaccine capable of inducing broadly neutralizing antibodies against HIV has led to insights into a range of autoimmune and chronic diseases, notably antibody-mediated clearance of amyloid beta plaques found in **Alzheimer's** patients.

In addition, precision HIV vaccine immunogen design has driven advances in structure-based vaccine approaches for other viruses, such as **respiratory syncytial virus**, a leading cause of lower respiratory tract infections in young children.



How is AIDS research helping people with cancer?

Experimental treatments for several types of cancer have grown directly out of AIDS research. Treating HIV involves blocking key receptors—proteins used by the virus to enter immune cells. One of these receptors, CXCR4, appears to **Sever** be an important target in treating **lung cancer**.

Researchers are now studying drugs originally designed to block CXCR4 in HIV patients to determine whether they might be used to fight this common form of cancer.

Several natural body hormones called growth factors promote the activity of HIV. Many of these hormones also accelerate the growth and spread of cancer cells. Blocking the activity of these hormones is a strategy first used experimentally to treat Kaposi's sarcoma, a cancer found in patients with HIV/AIDS. Now it is also being tested in bladder, vulvar, and breast cancers, and has shown some exciting recent success in treating colon cancer.

In addition, small proteins and drugs that can block the growth of new blood vessels (which is critical to the survival of tumor cells) were originally developed to treat Kapo-

Experimental treatments for several types of cancer have grown directly out of AIDS research.

si's sarcoma, but are now being tested in many other cancers as well. Finally, the protease inhibitor lopinavir, first developed to treat HIV, has been shown to be effective in attacking human papillomavirus, which can cause **cervical cancer**.

The profound immune suppression necessary for a bone marrow transplant to treat **leukemia** and other cancers often leads to devastating, even fatal, infections such as cytomegalovirus and Pneumocystis pneumonia, which also affect people with AIDS. New drugs to treat and prevent these infections in cancer patients have come directly from AIDS-targeted research.

Since HIV is a virus that attacks the immune system, what does AIDS research teach us about autoimmune disorders or immune-based therapies for other diseases?



A new class of anti-HIV drug that blocks a protein known as CCR5 ... is also being evaluated in inflammatory bowel disease and other autoimmune disorders.

HIV-positive people may develop autoimmune problems, such as **psoriasis** or blood abnormalities associated with **lupus**. For these autoimmune diseases, treatments developed for HIV/AIDS should also apply when the same conditions occur spontaneously. A new class of anti-HIV drug that blocks a protein known as CCR5, the key co-receptor for HIV's entry into cells, is also being evaluated in **inflammatory bowel disease** and other autoimmune disorders.

Certain hormones that modify the function of immune cells are now being tested as treatments for HIV. Some of the most recent include IL-12 and TNF (tumor necrosis factor)-alpha inhibitors, which may also boost the immune systems of cancer patients. In those patients, the hormones help destroy the residue of cancer after surgery, radiation, or chemotherapy. The TNF-alpha inhibitors may also be useful in combating the body wasting that accompanies AIDS and some forms of cancer.

How are new technologies developed for AIDS research advancing the diagnosis landscape?

New PCR tests, developed for diagnosing HIV, are now routinely used to rapidly detect a number of other infectious diseases...


One particle of HIV genetic material can be located among millions of other particles by using extraordinarily sensitive techniques known as PCR (polymerase chain reaction) and RT-PCR (reverse transcription PCR). New PCR tests, developed for diagnosing HIV, are now routinely used to rapidly detect a number of other infectious diseases, including hepatitis C, tuberculosis, chlamydia, influenza, Lyme disease, and many fungal infections.

These techniques have also made it possible to measure otherwise undetectable levels of **cancer** cells in people who appear to have been cured. This detection allows doctors


to initiate new therapy or to continue ongoing treatments that might otherwise have been discontinued.

Further, the discovery of HHV-8, a **herpes virus** linked to Kaposi's sarcoma, was made possible by a new application of PCR. This technique is now being used worldwide to seek possible infectious causes for diseases of unknown origins.

Also, studying immune dysfunction associated with HIV has driven advances in affordable, automated, and portable point-of-care devices that could have a range of clinical applications in resource-limited settings.




In which other ways is amfAR's work helping people with illnesses other than AIDS?



Advocacy efforts by amfAR and other organizations were instrumental in getting the Food and Drug Administration to institute fast-track procedures to speed the review of new treatments for all life-

threatening diseases. Fast-tracking has already been applied in the approval of treatments for conditions such as **Alzheimer's**, **AIDS**, and **cancer**.





Yes, I want to support amfAR's innovative HIV/AIDS research programs that are also helping to improve treatment for many other diseases.

☐ I've enclos	sed a check,	payable to amfAF	≀, in the an	mount of \$	
☐ Please cha	arge \$	to my credit o	ard:		
□ AmEx	□ Visa	☐ MasterCard	☐ Dis	cover	
Card Number				Expiration Date	
Name			Signature		
Address				City/State/Zip Code	
Phone #					
☐ I would like	e to make my	gift a recurring me	onthly pled	dge.	
☐ My compa	ny has a Mat	tching Gift Progran	n and I hav	ve enclosed the form.	
☐ I have inclu	uded amfAR	in my will.			
☐ I would like	e to receive r	egular updates on	amfAR's w	vork.	
My email a	ıddress is:			_	
Gifts to amfAR are	tax-deducti	ble as charitable c	ontribution	s. For information about making	
a gift of securities	or other non	cash assets, pleas	e call (212)) 806-1681.	
Federal employees	s and U.S. m	ilitary personnel ca	an support	amfAR through the	
Combined Federa	l Campaign (CFC #11996).			
☐ Please ser	nd me informa	ation about making	g a monthl	y contribution to amfAR.	
☐ Please ser	nd me informa	ation about includi	ng amfAR	in my will or other	
estate plar	is.				
☐ Please che	ck here if yo	u do not want amf	AR to shar	re your name with	
other orga	nizations.				
Learn more about	the latest in	amfAR-funded HIV	//AIDS rese	earch programs by visiting us	
•		· ·	For more in	nformation please contact us	
at (800) 39-amfAR	or at donors	@amfar.org.			

Detach and mail this form to:

amfAR, 120 Wall Street, 13th Floor, New York, NY 10005-3908.